Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease

Authors

Ana Paula Lacerda (ORCID: https://orcid.org/0000-0002-0122-4183)
Sharanya Ford
Remo Panaccione (ORCID: https://orcid.org/0000-0002-5247-940X)
Andrew Garrison
Marla C. Dubinsky (ORCID: https://orcid.org/0000-0003-4968-5795)
Colla Cunneen
Olivier Dewit (ORCID: https://orcid.org/0000-0003-3726-4854)
Samuel I. Anyanwu
Elena Dubcenco
Toshimitsu Fujii (ORCID: https://orcid.org/0000-0003-3048-7270)
Pascal Juillerat (ORCID: https://orcid.org/0000-0002-0947-5235)
Edward V. Loftus (ORCID: https://orcid.org/0000-0001-7199-6851)
Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
Irina Fish
Namita Joshi (ORCID: https://orcid.org/0000-0001-5577-2890)

Institutions

University of Bern (CH)
Tokyo Medical and Dental University (JP)
Cliniques Universitaires Saint-Luc (BE)
University of Calgary (CA)
University Hospital of Bern (CH)
AbbVie (United States) (US)
Mayo Clinic in Arizona (US)
Amsterdam University Medical Centers (NL)
University of Amsterdam (NL)
Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal: Inflammatory Bowel Diseases
Published: 2025-10-03
DOI: https://doi.org/10.1093/ibd/izaf250
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease

Ana Paula Lacerda, Sharanya Ford, Remo Panaccione, Andrew Garrison et al.

Oct 3, 2025

Inflammatory Bowel Diseases

Inflammatory Bowel Disease

article

Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease

Ana Paula Lacerda, Sharanya Ford, Remo Panaccione, Andrew Garrison, Marla C. Dubinsky, Colla Cunneen, Olivier Dewit, Samuel I. Anyanwu, Elena Dubcenco, Toshimitsu Fujii, Pascal Juillerat, Edward V. Loftus, Geert D’Haens, Irina Fish, Namita Joshi

October 3, 2025article en

Abstract

No abstract available for this paper.

Inflammatory Bowel DiseasesVol. 32(3)

University of Bern (CH), Tokyo Medical and Dental University (JP), Cliniques Universitaires Saint-Luc (BE), University of Calgary (CA), University Hospital of Bern (CH), AbbVie (United States) (US), Mayo Clinic in Arizona (US), Amsterdam University Medical Centers (NL), University of Amsterdam (NL), Icahn School of Medicine at Mount Sinai (US)

Openalex Percentile: Top 65%

Inflammatory Bowel Disease

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease — Ana Paula Lacerda, Sharanya Ford, et al. · Inflammatory Bowel Diseases (2025) | TGRS Research Map | TGRS